![LONSURF® (trifluridine and tipiracil) tablets Efficacy | Previously Treated Metastatic GEJ and Gastric Cancer Treatment LONSURF® (trifluridine and tipiracil) tablets Efficacy | Previously Treated Metastatic GEJ and Gastric Cancer Treatment](https://www.lonsurfhcp.com/Content/img/mGEJ/lonsurf-metastatic-gej-cancer-reduced-mortality-risk-mobile.png)
LONSURF® (trifluridine and tipiracil) tablets Efficacy | Previously Treated Metastatic GEJ and Gastric Cancer Treatment
![LONSURF® (trifluridine and tipiracil) tablets Efficacy | Previously Treated Metastatic GEJ and Gastric Cancer Treatment LONSURF® (trifluridine and tipiracil) tablets Efficacy | Previously Treated Metastatic GEJ and Gastric Cancer Treatment](https://www.lonsurfhcp.com/Content/img/mGEJ/lonsurf-metastatic-gej-cancer-reduced-progression-risk-mobile.png)
LONSURF® (trifluridine and tipiracil) tablets Efficacy | Previously Treated Metastatic GEJ and Gastric Cancer Treatment
![TAGS: A Phase 3, Randomised, Double-blind Study of Trifluridine/Tipiracil ( TAS-102) Versus Placebo in Patients With Refractory Metastatic Gastric Cancer. - ppt download TAGS: A Phase 3, Randomised, Double-blind Study of Trifluridine/Tipiracil ( TAS-102) Versus Placebo in Patients With Refractory Metastatic Gastric Cancer. - ppt download](https://slideplayer.com/slide/14899254/91/images/4/TAGS%3A+TAS-102+Gastric+Studya.jpg)
TAGS: A Phase 3, Randomised, Double-blind Study of Trifluridine/Tipiracil ( TAS-102) Versus Placebo in Patients With Refractory Metastatic Gastric Cancer. - ppt download
![Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/8fcc6ca4-b344-45ac-8c69-362ca4592a42/gr4_lrg.jpg)
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology
![Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs12094-016-1528-7/MediaObjects/12094_2016_1528_Fig2_HTML.gif)
Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase
![Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts | Anticancer Research Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts | Anticancer Research](https://ar.iiarjournals.org/content/anticanres/35/9/4605/F1.large.jpg)
Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts | Anticancer Research
![Targeted and novel therapy in advanced gastric cancer | Experimental Hematology & Oncology | Full Text Targeted and novel therapy in advanced gastric cancer | Experimental Hematology & Oncology | Full Text](https://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs40164-019-0149-6/MediaObjects/40164_2019_149_Fig1_HTML.png)
Targeted and novel therapy in advanced gastric cancer | Experimental Hematology & Oncology | Full Text
![Dihydroartemisinin suppresses proliferation, migration, the Wnt/β‑catenin pathway and EMT via TNKS in gastric cancer Corrigendum in /10.3892/ol.2021.13152 Dihydroartemisinin suppresses proliferation, migration, the Wnt/β‑catenin pathway and EMT via TNKS in gastric cancer Corrigendum in /10.3892/ol.2021.13152](https://www.spandidos-publications.com/article_images/ol/22/4/ol-22-04-12949-g00.jpg)
Dihydroartemisinin suppresses proliferation, migration, the Wnt/β‑catenin pathway and EMT via TNKS in gastric cancer Corrigendum in /10.3892/ol.2021.13152
![Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/0863f30f-8efe-4ba0-a570-7053cec36c69/gr1.gif)
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology
![Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts | Anticancer Research Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts | Anticancer Research](https://ar.iiarjournals.org/content/anticanres/35/9/4605/F1.medium.gif)
Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts | Anticancer Research
![Efficacy and safety of trifluridine/tipiracil plus ramucirumab in comparison with trifluridine/tipiracil monotherapy for patients with advanced gastric cancer–single institutional experience | Gastric Cancer Efficacy and safety of trifluridine/tipiracil plus ramucirumab in comparison with trifluridine/tipiracil monotherapy for patients with advanced gastric cancer–single institutional experience | Gastric Cancer](https://media.springernature.com/w200/springer-static/cover/journal/10120.jpg)
Efficacy and safety of trifluridine/tipiracil plus ramucirumab in comparison with trifluridine/tipiracil monotherapy for patients with advanced gastric cancer–single institutional experience | Gastric Cancer
OncLive - The Japanese Ministry of Health, Labour and Welfare has approved TAS-102 (trifluridine/tipiracil; Lonsurf) for the treatment of patients with unresectable advanced or recurrent gastric cancer that has progressed after chemotherapy.
![TAGS: A Phase 3, Randomised, Double-blind Study of Trifluridine/Tipiracil ( TAS-102) Versus Placebo in Patients With Refractory Metastatic Gastric Cancer. - ppt download TAGS: A Phase 3, Randomised, Double-blind Study of Trifluridine/Tipiracil ( TAS-102) Versus Placebo in Patients With Refractory Metastatic Gastric Cancer. - ppt download](https://slideplayer.com/slide/14899254/91/images/7/Primary+Endpoint+%E2%80%93+OS+OS+%28%25%29+FTD%2FTPI+Placebo+Time+%28months%29.jpg)
TAGS: A Phase 3, Randomised, Double-blind Study of Trifluridine/Tipiracil ( TAS-102) Versus Placebo in Patients With Refractory Metastatic Gastric Cancer. - ppt download
![Gastric Cancer Foundation FDA Grants Priority Review to TAS-102 for Gastric/GEJ Cancer | Gastric Cancer Foundation Gastric Cancer Foundation FDA Grants Priority Review to TAS-102 for Gastric/GEJ Cancer | Gastric Cancer Foundation](https://gastriccancer.org/wp-content/uploads/2018/11/680522_IMG_173101_HR.jpg)
Gastric Cancer Foundation FDA Grants Priority Review to TAS-102 for Gastric/GEJ Cancer | Gastric Cancer Foundation
![Evolving Immuno-Chemotherapeutic Paradigms in Esophageal and Gastric Cancers | Published in healthbook TIMES Oncology Hematology Evolving Immuno-Chemotherapeutic Paradigms in Esophageal and Gastric Cancers | Published in healthbook TIMES Oncology Hematology](https://s3.amazonaws.com/production.scholastica/public/attachments/a58eb50a-ea22-41f3-871e-1a99b9b073ef/large/image1.png)
Evolving Immuno-Chemotherapeutic Paradigms in Esophageal and Gastric Cancers | Published in healthbook TIMES Oncology Hematology
![Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Irinotecan Hydrochloride on Human Colorectal and Gastric Cancer Xenografts | Anticancer Research Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Irinotecan Hydrochloride on Human Colorectal and Gastric Cancer Xenografts | Anticancer Research](https://ar.iiarjournals.org/content/anticanres/35/3/1437/F1.large.jpg)
Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Irinotecan Hydrochloride on Human Colorectal and Gastric Cancer Xenografts | Anticancer Research
![Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Irinotecan Hydrochloride on Human Colorectal and Gastric Cancer Xenografts | Anticancer Research Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Irinotecan Hydrochloride on Human Colorectal and Gastric Cancer Xenografts | Anticancer Research](https://ar.iiarjournals.org/content/anticanres/35/3/1437/F2.large.jpg)